Abstract:Background Cell death during tissue injury leads to release of chromosomal DNA which is promptly degraded. However, short DNA fragments wrapped around nucleosomes survive longer in the bloodstream and can be isolated as circulating cell-free DNA (ccfDNA). Oncology field pioneered the use of cfDNA as clinical biomarker by identifying sequence modifications induced in cancer cells. Importantly, ccfDNA also retains the same epigenetic information as the tissue of origin. Despite major advances for disease diagnosis and therapy, coronary artery diseases (CAD) and associated conditions such acute myocardial infarction (AMI) or heart failure (HF) are responsible for leading number of deaths worldwide. Preventive and surveillance strategies with non-invasive testing are needed. Purpose Evaluation of ccfDNA methylation profiles as prognostic non-invasive biomarker for risk stratification of acute coronary syndromes and their potential application in preventive and surveillance strategies in other cardiovascular disorders. Methods CcfDNA isolated from citrate-plasma collected from our discovery cohort, comprising healthy controls, STEMI, NSTEMI and unstable angina (UA) patients, was analyzed applying Whole Genome Bisulfite Sequencing (WGBS) using a low-input BS-seq (PBAT) protocol. Computational analysis generated differentially methylated regions (DMRs) by tiling CpG areas and setting a threshold of minimal 25% methylation difference compared to the healthy group. To assess the validity of our findings, a selection of disease-specific DMRs were tested using targeted methylation sequencing protocol in a new set of patients. This procedure consisted in enzymatic conversion of ccfDNA methylated sites followed by probe-specific enrichment libraries and sequencing at a Novaseq 6000 platform. Results The study identified a total of 1941 DMRs and from those 486 were STEMI, 223 NSTEMI and 684 UA specific. From the identified DMRs, 74.13% from STEMI, 72.68% from NSTEMI and 61.62% from UA annotated with heart-related diseases using DisGeNET gene-disease associations. Interestingly, most of identified DMRs located within intronic regions (~60%) and also annotated as enhancers and lncRNAs. The independent validation with targeted methylation sequencing identified 566, 306 and 248 DMRs, respectively, and reduced the number of disease-specific DMRs to 171 in STEMI, 115 in NSTEMI and 82 in UA. Conclusion and Future Approaches Methylation profiles of ccfDNA showed potential as a biomarker to stratify the severity of acute coronary syndromes, a novel non-invasive detection methodology that could be extrapolated to risk stratification in other cardiovascular disease such as heart failure or coronary artery disease.

5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA As Candidate Diagnostic and Predictive Biomarkers for Coronary Artery Disease

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA As Diagnostic and Predictive Biomarkers for Coronary Artery Disease

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer’s Disease

Abstract 4135025: Inflammation-related 5-Hydroxymethylation Signatures As Markers for Clinical Presentations of Coronary Artery Disease

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA As Diagnostic Biomarkers for Late-Onset Alzheimer's Disease

A 5-Hydroxymethylcytosine-based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: the METHOD-2 Study

Methylome of circulating cell free DNA as a novel biomarker tool: from acute coronary syndrome to broader risk stratification of cardiovascular disease

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers

DNA 5-Hydroxymethylcytosines from Cell-free Circulating DNA As Diagnostic Biomarkers for Human Cancers

5-Hydroxymethylcytosine profiles in circulating cell-free DNA serve as potential biomarkers for diagnosis and classification of adenomyosis

5mC modification patterns provide novel direction for early acute myocardial infarction detection and personalized therapy

5-Hydroxymethylcytosine in circulating cell-free DNA as a potential diagnostic biomarker for SLE

Early Detection of Non-Small Cell Lung Cancer with Novel 5-Hydroxymethylcytosine DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma

MOESM1 of 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA As Diagnostic and Predictive Biomarkers for Coronary Artery Disease

5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

5-Hydroxymethylcytosines in Circulating Cell-Free DNA Reveal Vascular Complications of Type 2 Diabetes.

5-hydroxymethylcytosine Epigenetic Markers in COVID-19-Associated Acute Coronary Syndrome: Insights into Neutrophil Activation and PDE4D Upregulation

A 5-hydroxymethylcytosine-based noninvasive model for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma: The METHOD-2 study.

5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients

Cell-free DNA 5-hydroxymethylcytosine profiles of long non-coding RNA genes enable early detection and progression monitoring of human cancers